Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Ezetimibe can reduce the cardiovascular problems in diabetes patients, says a new study. The drug achieved greater reductions in LDL cholesterol than statins alone, resulting in lower risks of cardiovascular events in patients with diabetes and the benefits observed in diabetics were greater than in those without diabetes.

  • A large clinical trial in the US has found that omega-3 supplements will not slow cognitive decline in older people, debunking earlier research that a diet high in omega-3 fatty acids can protect brain health. The paper was published in the Journal of the American Medical Association.

    [adsense:336x280:8701650588]

  • The Mankind Pharma has taken an initiative to spread awareness about the importance of having strong bones, among the masses. The company has been championing this cause with their specialized ‘D3 Must Campaign’ across the country by reaching out to various schools, institutes and corporates.

  • Researchers from University of Southern California have revealed that if your brain gets a chance to learn from its mistakes, it will turn failures in life into positive experiences. The paper is published in the journal Nature Communications.

  • Finasteride and Dutasteride are in the family of drugs known as 5alpha-reductase inhibitors (5A-RIs). They are often prescribed for the treatment of male pattern hair loss, known as alopecia, and benign prostate enlargement (BPH). A new study has revealed that these commonly prescribed medicines may lead to adverse sexual side effects such as loss of libido or erectile dysfunction. The study  appear online in Endocrine Reviews and Metabolic Disorders.

  • A 40 to 80 day treatment with the antiparasitic medication benznidazole significantly reduced parasite activity in the blood, but not progression, of serious heart problems over a 5-year period among patients with established Chagas disease (CD) cardiomyopathy, results of the BENEFIT trial show.

Subscribe to Pharma News